DDInter667 DDInter1435
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Erlotinib {u} (Compound) resembles {v} (Compound) Vandetanib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Erlotinib {u} (Compound) treats {v} (Disease) kidney cancer
Erlotinib {u} (Compound) binds {v} (Gene) CYP1A2
Erlotinib {u} (Compound) upregulates {v} (Gene) IL1B
Erlotinib {u} (Compound) downregulates {v} (Gene) COX8A
Erlotinib {u} (Compound) causes {v} (Side Effect) Drug interaction
Erlotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Erlotinib (Compound) resembles Vandetanib (Compound)
Erlotinib (Compound) resembles Gefitinib (Compound)
Erlotinib (Compound) treats kidney cancer (Disease)
Erlotinib (Compound) binds CYP1A2 (Gene)
Erlotinib (Compound) upregulates IL1B (Gene)
Erlotinib (Compound) downregulates COX8A (Gene)
Erlotinib (Compound) causes Drug interaction (Side Effect)
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine